Glutamatergic Modulators: The Future of Treating Mood Disorders?

REFERENCES

• Kessler RC, Akiskal HS, Ames M, Prevalence and effects of mood disorders on work performance in a nationally representative sample of U.S. workers. Am J Psychiatry 2006;163:1561–8.
   PubMed Web of Science ®Google Scholar
• Murray CJ, Lopez AD. Evidence-based health policy—lessons from the Global Burden of Disease Study. Science 1996;274:740–3.
   PubMed Web of Science ®Google Scholar
• Insel TR, Scolnick EM. Cure therapeutics and strategic prevention: raising the bar for mental health research. Mol Psychiatry 2006;11:11–7.
   PubMed Web of Science ®Google Scholar
• Machado-Vieira R, Salvadore G, Luckenbaugh DA, Manji HK, Zarate CA Jr. Rapid onset of antidepressant action: a new paradigm in the research and treatment of major depressive disorder. J Clin Psychiatry 2008;69:946–58.
   PubMed Web of Science ®Google Scholar
• Fagiolini A, Kupfer DJ, Masalehdan A, Scott JA, Houck PR, Frank E. Functional impairment in the remission phase of bipolar disorder. Bipolar Disord 2005;7:281–5.
   PubMed Web of Science ®Google Scholar
• Judd LL, Akiskal HS, Schettler PJ, The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry 2002;59:530–7.
   PubMed Web of Science ®Google Scholar
• Tohen M, Hennen J, Zarate CM Jr, Two-year syndromal and functional recovery in 219 cases of first-episode major affective disorder with psychotic features. Am J Psychiatry 2000;157:220–8.
   PubMed Web of Science ®Google Scholar
• Trivedi MH, Rush AJ, Wisniewski SR, Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006;163:28–40.
   PubMed Web of Science ®Google Scholar
• Gitlin M. Treatment-resistant bipolar disorder. Mol Psychiatry 2006;11:227–40.
   PubMed Web of Science ®Google Scholar
• Baldessarini RJ, Perry R, Pike J. Factors associated with treatment nonadherence among US bipolar disorder patients. Hum Psychopharmacol 2008;23:95–105.
   PubMed Web of Science ®Google Scholar
• Machado-Vieira R, Manji HK, Zarate CA. The role of the tripartite glutamatergic synapse in the pathophysiology and therapeutics of mood disorders. Neuroscientist 2009;15:525–39.
   PubMed Web of Science ®Google Scholar
• Skolnick P, Legutko B, Li X, Bymaster FP. Current perspectives on the development of non-biogenic amine-based antidepressants. Pharmacol Res 2001;43:411–23.
   Google Scholar
• Machado-Vieira R, Salvadore G, Ibrahim I, Diaz-Granados N, Zarate CA. Targeting glutamatergic signaling for the development of novel therapeutics for mood disorders. Curr Pharm Des 2009;15:1595–611.
   PubMed Web of Science ®Google Scholar
• Hashimoto K, Sawa A, Iyo M. Increased levels of glutamate in brains from patients with mood disorders. Biol Psychiatry 2007;62:1310–6.
   PubMed Web of Science ®Google Scholar
• Scarr E, Pavey G, Sundram S, MacKinnon A, Dean B. Decreased hippocampal NMDA, but not kainate or AMPA receptors in bipolar disorder. Bipolar Disord 2003;5:257– 64.
   PubMed Web of Science ®Google Scholar
• Hasler G, Van Der Veen JW, Tumonis T, Meyers N, Shen J, Drevets WC. Reduced prefrontal glutamate/glutamine and gamma-aminobutyric acid levels in major depression determined using proton magnetic resonance spectroscopy. Arch Gen Psychiatry 2007;64:193–200.
   PubMed Web of Science ®Google Scholar
• Sanacora G, Gueorguieva R, Epperson CN, Subtype-specific alterations of gamma-aminobutyric acid and glutamate in patients with major depression. Arch Gen Psychiatry 2004;61:705–13.
   PubMed Web of Science ®Google Scholar
• Yildiz-Yesiloglu A, Ankerst DP. Neurochemical alterations of the brain in bipolar disorder and their implications for pathophysiology: a systematic review of the in vivo proton magnetic resonance spectroscopy findings. Prog Neuropsychopharmacol Biol Psychiatry 2006;30:969–95.
   PubMed Web of Science ®Google Scholar
• Collingridge GL, Bliss TV. Memories of NMDA receptors and LTP. Trends Neurosci 1995;18:54–6.
   PubMed Web of Science ®Google Scholar
• Schloesser RJ, Huang J, Klein PS, Manji HK. Cellular plasticity cascades in the pathophysiology and treatment of bipolar disorder. Neuropsychopharmacology 2008;33:110–3.
   PubMed Web of Science ®Google Scholar
• McClung CA, Nestler EJ. Neuroplasticity mediated by altered gene expression. Neuropsychopharmacology 2008;33:3–17.
   PubMed Web of Science ®Google Scholar
• Manji HK, Duman RS. Impairments of neuroplasticity and cellular resilience in severe mood disorders: implications for the development of novel therapeutics. Psychopharmacol Bull 2001;35:5–49.
   PubMedGoogle Scholar
• Choudary PV, Molnar M, Evans SJ, Altered cortical glutamatergic and GABAergic signal transmission with glial involvement in depression. Proc Natl Acad Sci U S A 2005;102:15653–8.
   PubMed Web of Science ®Google Scholar
• McCullumsmith RE, Kristiansen LV, Beneyto M, Scarr E, Dean B, Meador-Woodruff JH. Decreased NR1, NR2A, and SAP102 transcript expression in the hippocampus in bipolar disorder. Brain Res 2007;1127:108–18.
   Google Scholar
• Miller TM, Cleveland DW. Medicine. Treating neurodegenerative diseases with antibiotics. Science 2005;307:361–2.
   PubMedGoogle Scholar
• Mineur YS, Picciotto MR, Sanacora G. Antidepressant-like effects of ceftriaxone in male C57BL/6J mice. Biol Psychiatry 2007;61:250–2.
   PubMed Web of Science ®Google Scholar
• Rothstein JD, Patel S, Regan MR, Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature 2005;433:73–7.
   PubMed Web of Science ®Google Scholar
• Hassel B, Iversen EG, Gjerstad L, Tauboll E. Up-regulation of hippocampal glutamate transport during chronic treatment with sodium valproate. J Neurochem 2001;77:1285–92.
   PubMed Web of Science ®Google Scholar
• Ueda Y, Willmore LJ. Molecular regulation of glutamate and GABA transporter proteins by valproic acid in rat hippocampus during epileptogenesis. Exp Brain Res 2000;133:334–9.
   PubMedGoogle Scholar
• Lee Y, Gaskins D, Anand A, Shekhar A. Glia mechanisms in mood regulation: a novel model of mood disorders. Psychopharmacology (Berl) 2007;191:55–65.
   Google Scholar
• Uezato A, Meador-Woodruff JH, McCullumsmith RE. Vesicular glutamate transporter mRNA expression in the medial temporal lobe in major depressive disorder, bipolar disorder, and schizophrenia. Bipolar Disord 2009;11:711–25.
   Google Scholar
• Tordera RM, Pei Q, Sharp T. Evidence for increased expression of the vesicular glutamate transporter, VGLUT1, by a course of antidepressant treatment. J Neurochem 2005;94:875–83.
   PubMed Web of Science ®Google Scholar
• Tordera RM, Totterdell S, Wojcik SM, Enhanced anxiety, depressive-like behaviour and impaired recognition memory in mice with reduced expression of the vesicular glutamate transporter 1 (VGLUT1). Eur J Neurosci 2007;25:281–90.
   PubMed Web of Science ®Google Scholar
• Moutsimilli L, Farley S, Dumas S, El Mestikawy S, Giros B, Tzavara ET. Selective cortical VGLUT1 increase as a marker for antidepressant activity. Neuropharmacology 2005;49:890–900.
   PubMed Web of Science ®Google Scholar
• Hashimoto R, Hough C, Nakazawa T, Yamamoto T, Chuang DM. Lithium protection against glutamate excitotoxicity in rat cerebral cortical neurons: involvement of NMDA receptor inhibition possibly by decreasing NR2B tyrosine phosphorylation. J Neurochem 2002;80:589–97.
   PubMed Web of Science ®Google Scholar
• Thompson CM, Davis E, Carrigan CN, Cox HD, Bridges RJ, Gerdes JM. Inhibitor of the glutamate vesicular transporter (VGLUT). Curr Med Chem 2005;12:2041–56.
   Google Scholar
• Beneyto M, Kristiansen LV, Oni-Orisan A, McCullumsmith RE, Meador-Woodruff JH. Abnormal glutamate receptor expression in the medial temporal lobe in schizophrenia and mood disorders. Neuropsychopharmacology 2007;32:1888–902.
   PubMed Web of Science ®Google Scholar
• Meador-Woodruff JH, Hogg AJ Jr, Smith RE. Striatal ionotropic glutamate receptor expression in schizophrenia, bipolar disorder, and major depressive disorder. Brain Res Bull 2001;55:631–40.
   PubMed Web of Science ®Google Scholar
• Devon RS, Anderson S, Teague PW, Identification of polymorphisms within Disrupted in Schizophrenia 1 and Disrupted in Schizophrenia 2, and an investigation of their association with schizophrenia and bipolar affective disorder. Psychiatr Genet 2001;11:71–8.
   PubMedGoogle Scholar
• Marti SB, Cichon S, Propping P, Nothen M. Metabotropic glutamate receptor 3 (GRM3) gene variation is not associated with schizophrenia or bipolar affective disorder in the German population. Am J Med Genet 2002;114:46–50.
   PubMed Web of Science ®Google Scholar
• Chourbaji S, Vogt MA, Fumagalli F, AMPA receptor subunit 1 (GluR-A) knockout mice model the glutamate hypothesis of depression. FASEB J 2008;22:3129–34.
   Google Scholar
• Zarate CA, Manji HK. The role of AMPA receptor modulation in the treatment of neuropsychiatric diseases. Exp Neurol 2008;211:7–10.
   PubMed Web of Science ®Google Scholar
• Miu P, Jarvie KR, Radhakrishnan V, Novel AMPA receptor potentiators LY392098 and LY404187: effects on recombinant human AMPA receptors in vitro. Neuropharmacology 2001;40:976–83.
   Google Scholar
• Quiroz JA, Singh J, Gould TD, Denicoff KD, Zarate CA, Manji HK. Emerging experimental therapeutics for bipolar disorder: clues from the molecular pathophysiology. Mol Psychiatry 2004;9:756–76.
   PubMed Web of Science ®Google Scholar
• Sanacora G, Zarate CA, Krystal JH, Manji HK. Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nat Rev Drug Discov 2008;7:426–37.
   PubMed Web of Science ®Google Scholar
• Black MD. Therapeutic potential of positive AMPA modulators and their relationship to AMPA receptor subunits. A review of preclinical data. Psychopharmacology (Berl) 2005;179:154–63.
   PubMed Web of Science ®Google Scholar
• Lynch G. AMPA receptor modulators as cognitive enhancers. Curr Opin Pharmacol 2004;4:4–11.
   PubMed Web of Science ®Google Scholar
• O’Neill MJ, Bleakman D, Zimmerman DM, Nisenbaum ES. AMPA receptor potentiators for the treatment of CNS disorders. Curr Drug Targets CNS Neurol Disord 2004;3:181–94.
   PubMedGoogle Scholar
• Nowak G, Trullas R, Layer RT, Skolnick P, Paul IA. Adaptive changes in the N-methyl-D-aspartate receptor complex after chronic treatment with imipramine and 1-aminocyclopropanecarboxylic acid. J Pharmacol Exp Ther 1993;265:1380–6.
   PubMed Web of Science ®Google Scholar
• Paul IA, Nowak G, Layer RT, Popik P, Skolnick P. Adaptation of the N-methyl-D-aspartate receptor complex following chronic antidepressant treatments. J Pharmacol Exp Ther 1994;269:95–102.
   PubMed Web of Science ®Google Scholar
• Law AJ, Deakin JF. Asymmetrical reductions of hippocampal NMDAR1 glutamate receptor mRNA in the psychoses. Neuroreport 2001;12:2971–4.
   PubMed Web of Science ®Google Scholar
• Nudmamud-Thanoi S, Reynolds GP. The NR1 subunit of the glutamate/NMDA receptor in the superior temporal cortex in schizophrenia and affective disorders. Neurosci Lett 2004;372:173–7.
   PubMed Web of Science ®Google Scholar
• Toro C, Deakin JF. NMDA receptor subunit NRI and postsynaptic protein PSD-95 in hippocampus and orbitofrontal cortex in schizophrenia and mood disorder. Schizophr Res 2005;80:323–30.
   Google Scholar
• Itokawa M, Yamada K, Iwayama-Shigeno Y, Ishitsuka Y, Detera-Wadleigh S, Yoshikawa T. Genetic analysis of a functional GRIN2A promoter (GT)n repeat in bipolar disorder pedigrees in humans. Neurosci Lett 2003;345:53–6.
   PubMed Web of Science ®Google Scholar
• Martucci L, Wong AH, De Luca V, N-methyl-D-aspartate receptor NR2B subunit gene GRIN2B in schizophrenia and bipolar disorder: polymorphisms and mRNA levels. Schizophr Res 2006;84:214–21.
   PubMedGoogle Scholar
• Mundo E, Tharmalingham S, Neves-Pereira M, Evidence that the N-methyl-D-aspartate subunit 1 receptor gene (GRIN1) confers susceptibility to bipolar disorder. Mol Psychiatry 2003;8:241–5.
   Google Scholar
• Maeng S, Zarate CA Jr, Du J, Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol Psychiatry 2008;63:349–52.
   PubMed Web of Science ®Google Scholar
• Moryl E, Danysz W, Quack G. Potential antidepressive properties of amantadine, memantine and bifemelane. Pharmacol Toxicol 1993;72:394–7.
   PubMedGoogle Scholar
• Papp M, Moryl E. Antidepressant activity of non-competitive and competitive NMDA receptor antagonists in a chronic mild stress model of depression. Eur J Pharmacol 1994;263:1–7.
   PubMed Web of Science ®Google Scholar
• Trullas R, Skolnick P. Functional antagonists at the NMDA receptor complex exhibit antidepressant actions. Eur J Pharmacol 1990;185:1–10.
   PubMed Web of Science ®Google Scholar
• Zarate CA Jr, Singh JB, Carlson PJ, A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 2006;63:856–64.
   PubMed Web of Science ®Google Scholar
• Borza I, Bozo E, Barta-Szalai G, Selective NR1/2B N-methyl-D-aspartate receptor antagonists among indole-2-carboxamides and benzimidazole-2-carboxamides. J Med Chem 2007;50:901–14.
   Google Scholar
• Suetake-Koga S, Shimazaki T, Takamori K, In vitro and antinociceptive profile of HON0001, an orally active NMDA receptor NR2B subunit antagonist. Pharmacol Biochem Behav 2006;84:134–41.
   Google Scholar
• Preskorn SH, Baker B, Kolluri S, Menniti FS, Krams M, Landen JW. An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder. J Clin Psychopharmacol 2008;28:631–7.
   PubMed Web of Science ®Google Scholar
• Zarate CA, Singh J, Quiroz JA, A double-blind, placebo-controlled study of memantine in the treatment of major depression. Am J Psychiatry 2006;163:153–5.
   PubMed Web of Science ®Google Scholar
• Zarate CA Jr, Du J, Quiroz J, Regulation of cellular plasticity cascades in the pathophysiology and treatment of mood disorders: role of the glutamatergic system. Ann N Y Acad Sci 2003;1003:273–91.
   PubMed Web of Science ®Google Scholar
• Schiffer HH, Heinemann SF. Association of the human kainate receptor GluR7 gene (GRIK3) with recurrent major depressive disorder. Am J Med Genet B Neuropsychiatr Genet 2007;144B:20–6.
   Google Scholar
• Wilson GM, Flibotte S, Chopra V, Melnyk BL, Honer WG, Holt RA. DNA copy-number analysis in bipolar disorder and schizophrenia reveals aberrations in genes involved in glutamate signaling. Hum Mol Genet 2006;15:743–9.
   PubMed Web of Science ®Google Scholar
• Pickard BS, Malloy MP, Christoforou A, Cytogenetic and genetic evidence supports a role for the kainate-type glutamate receptor gene, GRIK4, in schizophrenia and bipolar disorder. Mol Psychiatry 2006;11:847–57.
   PubMed Web of Science ®Google Scholar
• Laje G, Paddock S, Manji H, Genetic markers of suicidal ideation emerging during citalopram treatment of major depression. Am J Psychiatry 2007;164:1530–8.
   PubMed Web of Science ®Google Scholar
• Menke A, Lucae S, Kloiber S, Genetic markers within glutamate receptors associated with antidepressant treatment-emergent suicidal ideation. Am J Psychiatry 2008;165:917–8.
   PubMed Web of Science ®Google Scholar
• Paddock S, Laje G, Charney D, Association of GRIK4 with outcome of antidepressant treatment in the STAR*D cohort. Am J Psychiatry 2007;164:1181–8.
   PubMed Web of Science ®Google Scholar
• Shaltiel G, Maeng S, Malkesman O, Evidence for the involvement of the kainate receptor subunit GluR6 (GRIK2) in mediating behavioral displays related to behavioral symptoms of mania. Mol Psychiatry 2008;13:858–72.
   PubMed Web of Science ®Google Scholar
• Chaki S, Hirota S, Funakoshi T, Anxiolytic-like and antidepressant-like activities of MCL0129 (1-[(S)-2-(4-fluorophenyl)-2-(4-isopropylpiperadin-1-yl)ethyl]-4-[4-(2-met hoxynaphthalen-1-yl)butyl]piperazine), a novel and potent nonpeptide antagonist of the melanocortin-4 receptor. J Pharmacol Exp Ther 2003;304:818–26.
   PubMed Web of Science ®Google Scholar
• Cosford ND, Tehrani L, Roppe J, 3-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]-pyridine: a potent and highly selective metabotropic glutamate subtype 5 receptor antagonist with anxiolytic activity. J Med Chem 2003;46:204–6.
   PubMed Web of Science ®Google Scholar
• Cryan JF, Kelly PH, Neijt HC, Sansig G, Flor PJ, Van Der Putten H. Antidepressant and anxiolytic-like effects in mice lacking the group III metabotropic glutamate receptor mGluR7. Eur J Neurosci 2003;17:2409–17.
   PubMed Web of Science ®Google Scholar
• Gasparini F, Bruno V, Battaglia G, (R,S)-4-phosphonophenylglycine, a potent and selective group III metabotropic glutamate receptor agonist, is anticonvulsive and neuroprotective in vivo. J Pharmacol Exp Ther 1999;289:1678–87.
   PubMed Web of Science ®Google Scholar
• Maiese K, Vincent A, Lin SH, Shaw T. Group I and group III metabotropic glutamate receptor subtypes provide enhanced neuroprotection. J Neurosci Res 2000;62:257–72.
   Google Scholar
• Palucha A, Tatarczynska E, Branski P, Group III mGlu receptor agonists produce anxiolytic- and antidepressant-like effects after central administration in rats. Neuropharmacology 2004;46:151–9.
   PubMed Web of Science ®Google Scholar
• Schoepp DD, Wright RA, Levine LR, Gaydos B, Potter WZ. LY354740, an mGlu2/3 receptor agonist as a novel approach to treat anxiety/stress. Stress 2003;6:189–97.
   PubMed Web of Science ®Google Scholar
• Li X, Need AB, Baez M, Witkin JM. Metabotropic glutamate 5 receptor antagonism is associated with antidepressant-like effects in mice. J Pharmacol Exp Ther 2006;319:254–9.
   PubMed Web of Science ®Google Scholar
• Wieronska JM, Szewczyk B, Branski P, Palucha A, Pilc A. Antidepressant-like effect of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist in the olfactory bulbectomized rats. Amino Acids 2002;23:213–6.
   PubMed Web of Science ®Google Scholar
• Yoshimizu T, Chaki S. Increased cell proliferation in the adult mouse hippocampus following chronic administration of group II metabotropic glutamate receptor antagonist, MGS0039. Biochem Biophys Res Commun 2004;315:493–6.
   PubMed Web of Science ®Google Scholar
• Yoshimizu T, Shimazaki T, Ito A, Chaki S. An mGluR2/3 antagonist, MGS0039, exerts antidepressant and anxiolytic effects in behavioral models in rats. Psychopharmacology (Berl) 2006;186:587–93.
   PubMed Web of Science ®Google Scholar
• Palucha A, Klak K, Branski P, Van Der Putten H, Flor PJ, Pilc A. Activation of the mGlu7 receptor elicits antidepressant-like effects in mice. Psychopharmacology (Berl) 2007;194:555– 62.
   PubMed Web of Science ®Google Scholar
• Karolewicz B, Szebeni K, Gilmore T, Maciag D, Stockmeier CA, Ordway GA. Elevated levels of NR2A and PSD-95 in the lateral amygdala in depression. Int J Neuropsychopharmacol 2009;12:143–53.
   Web of Science ®Google Scholar
• Clinton SM, Meador-Woodruff JH. Abnormalities of the NMDA receptor and associated intracellular molecules in the thalamus in schizophrenia and bipolar disorder. Neuropsychopharmacology 2004;29:1353–62.
   Google Scholar
• Kristiansen LV, Meador-Woodruff JH. Abnormal striatal expression of transcripts encoding NMDA interacting PSD proteins in schizophrenia, bipolar disorder and major depression. Schizophr Res 2005;78:87–93.
   Google Scholar
• Frizzo ME, Dall’Onder LP, Dalcin KB, Souza DO. Riluzole enhances glutamate uptake in rat astrocyte cultures. Cell Mol Neurobiol 2004;24:123–8.
   PubMed Web of Science ®Google Scholar
• Dagci T, Yilmaz O, Taskiran D, Peker G. Neuroprotective agents: is effective on toxicity in glial cells? Cell Mol Neurobiol 2007;27:171–7.
   PubMed Web of Science ®Google Scholar
• Zarate CA Jr, Payne JL, Quiroz J, An open-label trial of riluzole in patients with treatment-resistant major depression. Am J Psychiatry 2004;161:171–4.
   PubMed Web of Science ®Google Scholar
• Zarate CA Jr, Quiroz JA, Singh JB, An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression. Biol Psychiatry 2005;57:430–2.
   PubMed Web of Science ®Google Scholar
• Sanacora G, Kendell SF, Levin Y, Preliminary evidence of riluzole efficacy in antidepressant-treated patients with residual depressive symptoms. Biol Psychiatry 2007;61:822–5.
   PubMed Web of Science ®Google Scholar
• Coric V, Taskiran S, Pittenger C, Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial. Biol Psychiatry 2005;58:424–8.
   PubMed Web of Science ®Google Scholar
• Mathew SJ, Keegan K, Smith L. Glutamate modulators as novel interventions for mood disorders. Rev Bras Psiquiatr 2005;27:243–8.
   Google Scholar
• Banasr M, Duman RS. Glial loss in the prefrontal cortex is sufficient to induce depressive-like behaviors. Biol Psychiatry 2008;64:863–70.
   PubMed Web of Science ®Google Scholar
• Lourenco Da Silva A, Hoffmann A, Dietrich MO, Dall’Igna OP, Souza DO, Lara DR. Effect of riluzole on MK-801 and amphetamine-induced hyperlocomotion. Neuropsychobiology 2003;48:27–30.
   Google Scholar
• Moghaddam B, Adams B, Verma A, Daly D. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci 1997;17:2921–7.
   PubMed Web of Science ®Google Scholar
• Zarate CA, Quiroz J, Payne J, Manji HK. Modulators of the glutamatergic system: implications for the development of improved therapeutics in mood disorders. Psychopharmacol Bull 2002;36:35–83.
   PubMedGoogle Scholar
• Aguado L, San Antonio A, Perez L, del Valle R, Gomez J. Effects of the NMDA receptor antagonist ketamine on flavor memory: conditioned aversion, latent inhibition, and habituation of neophobia. Behav Neural Biol 1994;61:271–81.
   PubMedGoogle Scholar
• Garcia LS, Comim CM, Valvassori SS, Acute administration of ketamine induces antidepressant-like effects in the forced swimming test and increases BDNF levels in the rat hippocampus. Prog Neuropsychopharmacol Biol Psychiatry 2008;32:140–4.
   PubMed Web of Science ®Google Scholar
• Mickley GA, Schaldach MA, Snyder KJ, Ketamine blocks a conditioned taste aversion (CTA) in neonatal rats. Physiol Behav 1998;64:381–90.
   Google Scholar
• Silvestre JS, Nadal R, Pallares M, Ferre N. Acute effects of ketamine in the holeboard, the elevated-plus maze, and the social interaction test in Wistar rats. Depress Anxiety 1997;5:29–33.
   Google Scholar
• Berman RM, Cappiello A, Anand A, Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 2000;47:351–4.
   PubMed Web of Science ®Google Scholar
• Entsuah AR, Huang H, Thase ME. Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo. J Clin Psychiatry 2001;62:869–77.
   PubMed Web of Science ®Google Scholar
• Thase ME, Haight BR, Richard N, Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: a meta-analysis of original data from 7 randomized controlled trials. J Clin Psychiatry 2005;66:974–81.
   PubMed Web of Science ®Google Scholar
• Phelps LE, Brutsche NE, Moral JR, Luckenbaugh DA, Manji HK, Zarate CA. Family history of alcohol dependence and initial antidepressant response to an N-methyl-D-aspartate antagonist. Biol Psychiatry 2009;65:181–4.
   PubMed Web of Science ®Google Scholar
• DiazGranados N, Ibrahim I, Brutsche NE, Rapid resolution of suicidal ideation after a single infusion of ketamine in patients with treatment-resistant major depression. J Clin Psychiatry (in press).
   Google Scholar
• aan het Rot M, Collins KA, Murrough JW, Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol Psychiatry 2010;67:139–45.
   PubMed Web of Science ®Google Scholar
• Goforth HW, Holsinger T. Rapid relief of severe major depressive disorder by use of preoperative ketamine and electroconvulsive therapy. J ECT 2007;23:23–5.
   PubMed Web of Science ®Google Scholar
• Kudoh A, Takahira Y, Katagai H, Takazawa T. Small-dose ketamine improves the postoperative state of depressed patients. Anesth Analg 2002;95:114–8.
   PubMed Web of Science ®Google Scholar
• Correll GE, Futter GE. Two case studies of patients with major depressive disorder given low-dose (subanesthetic) ketamine infusions. Pain Med 2006;7:92–5.
   PubMed Web of Science ®Google Scholar
• Liebrenz M, Stohler R, Borgeat A. Repeated intravenous ketamine therapy in a patient with treatment-resistant major depression. World J Biol Psychiatry 2007:1–4.
   Google Scholar
• Ostroff R, Gonzales M, Sanacora G. Antidepressant effect of ketamine during ECT. Am J Psychiatry 2005;162: 1385–6.
   PubMed Web of Science ®Google Scholar
• Perry EB Jr, Cramer JA, Cho HS, Psychiatric safety of ketamine in psychopharmacology research. Psychopharmacology (Berl) 2007;192:253–60.
   PubMed Web of Science ®Google Scholar
• Krystal JH, Petrakis IL, Krupitsky E, Schutz C, Trevisan L, D’Souza DC. NMDA receptor antagonism and the ethanol intoxication signal: from alcoholism risk to pharmacotherapy. Ann N Y Acad Sci 2003;1003:176–84.
   PubMed Web of Science ®Google Scholar
• Petrakis IL, Limoncelli D, Gueorguieva R, Altered NMDA glutamate receptor antagonist response in individuals with a family vulnerability to alcoholism. Am J Psychiatry 2004;161:1776–82.
   PubMed Web of Science ®Google Scholar
• Schumann G, Johann M, Frank J, Systematic analysis of glutamatergic neurotransmission genes in alcohol dependence and adolescent risky drinking behavior. Arch Gen Psychiatry 2008;65:826–38.
   Google Scholar
• Petrenko AB, Yamakura T, Fujiwara N, Askalany AR, Baba H, Sakimura K. Reduced sensitivity to ketamine and pentobarbital in mice lacking the N-methyl-D-aspartate receptor GluRepsilon1 subunit. Anesth Analg 2004;99:1136–40, table of contents.
   Google Scholar
• Boyce-Rustay JM, Holmes A. Genetic inactivation of the NMDA receptor NR2A subunit has anxiolytic- and antide- pressant-like effects in mice. Neuropsychopharmacology 2006; 31:2405–14.
   PubMed Web of Science ®Google Scholar
• Salvadore G, Cornwell BR, Colon-Rosario V, Increased anterior cingulate cortical activity in response to fearful faces: a neurophysiological biomarker that predicts rapid antidepressant response to ketamine. Biol Psychiatry 2009;65:289–95.
   PubMed Web of Science ®Google Scholar
• Langguth B, Wiegand R, Kharraz A, Pre-treatment anterior cingulate activity as a predictor of antidepressant response to repetitive transcranial magnetic stimulation (rTMS). Neuro Endocrinol Lett 2007;28:633–8.
   PubMed Web of Science ®Google Scholar
• Mayberg HS, Brannan SK, Mahurin RK, Cingulate function in depression: a potential predictor of treatment response. Neuroreport 1997;8:1057–61.
   PubMed Web of Science ®Google Scholar
• McCormick LM, Boles Ponto LL, Pierson RK, Johnson HJ, Magnotta V, Brumm MC. Metabolic correlates of antidepressant and antipsychotic response in patients with psychotic depression undergoing electroconvulsive therapy. J ECT 2007;23:265–73.
   Google Scholar
• Pizzagalli D, Pascual-Marqui RD, Nitschke JB, Anterior cingulate activity as a predictor of degree of treatment response in major depression: evidence from brain electrical tomography analysis. Am J Psychiatry 2001;158:405– 15.
   PubMed Web of Science ®Google Scholar
• Wu J, Buchsbaum MS, Gillin JC, Prediction of antidepressant effects of sleep deprivation by metabolic rates in the ventral anterior cingulate and medial prefrontal cortex. Am J Psychiatry 1999;156:1149–58.
   PubMed Web of Science ®Google Scholar
• Machado-Vieira R, Yuan P, Brutsche NE, Brain-derived neurotrophic factor and initial antidepressant response to an N-methyl-D-aspartate antagonist. J Clin Psychiatry 2009;70:1662–6.
   PubMed Web of Science ®Google Scholar